Medincell

MEDCL · Euronext Paris · France

Public Market Listing

MEDCLEuronext Paris

Euronext Paris primary exchange listing

Live quotes, historical charts, and market capitalization for Medincell are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(2 total)
2Total Assets
2Approved
0Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Approved
Dopamine D2 and serotonin 5-HT2A/5-HT2C receptors (antagonist)Small molecule
Schizophrenia
Approved
Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule
SchizophreniaBipolar Disorder

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

9 October 2026ApprovalOlanzapine (TV-44749)FDA approves WELTRUZA for schizophrenia
US, FDA · Teva Pharmaceuticals · Source ↗
8 October 2026ApprovalOlanzapine (Weltruza)FDA Boxed Warning on Weltruza (NDA219007)
US, FDA · FDA · Source ↗
May 2026Filing acceptedOlanzapine (TV-44749)EMA accepts MAA for olanzapine LAI
EU, EMA · Teva Pharmaceuticals · Source ↗

Financial reports

No financial reports recorded.